FDA authorizes limited prescriptions of Paxlovid by pharmacists
The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization.
Related News Articles
Headline
The AHA’s social media toolkit for spreading awareness of the flu focuses on the beginning of fall and the availability of the flu vaccine for at-risk,…
Headline
Measles cases have been reported by 42 states and jurisdictions this year, with 1,563 total nationwide, according to the latest data released yesterday by the…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
AHA’s latest social media toolkit for spreading awareness of the flu focuses on the availability of the flu vaccine for at-risk, vulnerable populations as flu…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Centers for Disease Control and Prevention Sept. 24 released its annual report on national sexually transmitted disease data, reporting a 9% decline in STD…